Novo Nordisk said Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the FDA has approved Ozempic tablets in 1.5 milligram, 4 milligram, and 9 milligram doses. The new Ozempic name is intended to help patients and healthcare professionals more easily recognize the available treatment options for type 2 diabetes. Semaglutide tablets at 3 mg, 7 mg, and 14 mg doses have been available under the brand name Rybelsus for diabetes. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
